On June 8, Sino Biopharmaceutical fell 3.22% in regular trading, trading at HK$4.51/share, with trading volume of HK$155 million.

On the news front, Morgan Stanley recently issued a research report cutting the target price from HK$8.3 to HK$7.8 while maintaining an Overweight rating. The bank incorporated the newly in-licensed bepirovirsen (HBV ASO), expected to contribute revenue from 2027 onward, while removing dividend income assumptions from Sinovac LS starting from 2026 per management guidance. As a result, EPS forecasts for 2026 through 2028 were lowered by 8%, 7%, and 7% respectively. Additionally, working capital and capital expenditure assumptions were adjusted to better reflect recent operating trends.

The broader pharmaceutical sector experienced systemic selling pressure on the same day, with Luye Pharma down 4.3%, Hengrui Pharma down 3.85%, CSPC Pharma down 3.45%, and Hansoh Pharma down 2.39%, amplifying individual stock declines across the industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)